Skip to main content
    P

    PDS Biotechnology Corp (PDSB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.89
    -0.03 (-3.28%)

    Market Cap: $113.39M

    Last updated: Nov 17, 2026 at 4:43 PM ET

    PDS Biotechnology Corp (PDSB) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    PDS Biotechnology (PDSB) has a market cap of $113.39M and an enterprise value of $98.15M. Its share count is up 53.48% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 13.44% below the market cap, as cash exceeds debt.

    Market Cap$113.39M
    Enterprise Value$98.15M
    Latest price (Nov 17, 2026)$0.89

    Key Dates

    The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 29, 2027 (expected)
    Last Earnings DateNov 13, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 29.24% in the quarter ended Sep 30, 2026 and grew 39.80% a year over 2 years.

    Shares Outstanding71.94M
    Shares Change (YoY)+53.48%
    Shares Change (QoQ)+29.24%
    Share Count Growth (2Y CAGR)+39.80%

    Price Statistics

    The stock is up 6.34% over 52 weeks and trades 11.88% below its 50-day average.

    Beta (1Y)2.44
    52-Week Change+6.34%
    1-Month Change-2.48%
    3-Month Change+345.34%
    6-Month Change-10.62%
    5-Year Change-88.04%
    10-Year Change-99.31%
    Total Return (1Y)+6.34%
    Total Return (3Y CAGR)-47.81%
    Total Return (5Y CAGR)-38.47%
    Max Drawdown (1Y)-85.97%
    Max Drawdown (3Y)-96.95%
    Sharpe Ratio (1Y)0.07
    Correlation with SPY (1Y)0.19
    50-Day Average$1.01
    200-Day Average$0.84
    52-Week Range$0.20 to $1.79
    RSI (14 Days)41.5
    Average Volume (20 Days)5.73M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.62x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio3.62x
    Quick Ratio3.62x
    Debt / Equity0.00x
    Interest Coverage-3.52x

    Returns and Efficiency

    Return on invested capital is -149.78% over the last 12 months, against a 5-year average of -87.00%.

    Return on Equity (ROE)-239.22%
    Return on Assets (ROA)-173.83%
    Return on Invested Capital (ROIC)-149.78%
    Return on Capital Employed (ROCE)-189.60%
    ROA (5Y Average)-69.31%
    ROIC (5Y Average)-87.00%

    Scores

    PDSB has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Gross Profit-$15.13K
    Operating Income-$25.59M
    Pretax Income-$32.28M
    Net Income-$32.28M
    EBITDA-$23.79M
    EBIT-$25.59M
    Reported EPS (TTM)-$0.56

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 72.70% of the $18.57M in total assets.

    Cash and Equivalents$15.25M
    Total Debt$1.09K
    Net Cash$15.24M
    Net Cash Per Share$0.21
    Working Capital$13.30M
    Shareholder Equity$13.50M
    Book Value Per Share$0.19
    Total Assets$18.57M
    Total Liabilities$5.08M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$19.09M
    FCF Per Share-$0.16
    Depreciation and Amortization$1.80M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Book Value Per Share Growth (2Y CAGR)-50.83%
    Tangible Book Per Share Growth (2Y CAGR)-50.83%

    Revenue and profit by year

    Dividends and Yields

    PDSB does not pay a dividend.

    Buyback Yield-40.35%
    Shareholder Yield-40.35%

    Stock Splits

    The last split was a 1-for-20 reverse split on Mar 18, 2019.

    Last Split DateMar 18, 2019
    Split TypeReverse split
    Split Ratio1:20

    Peer Position

    Against 3 similar companies, PDSB has the 3rd highest ROIC.

    ROIC-149.78% vs -51.32% median
    Revenue Growth (Trailing 4 Quarters, YoY)-100.00% vs -57.30% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About PDSB

    What is PDSB's market cap?

    PDS Biotechnology has a market cap of $113.39M. Its enterprise value, which adds debt and subtracts cash, is $98.15M.

    How many shares of PDSB are outstanding?

    PDS Biotechnology has 71.94M shares outstanding. The count is up 53.48% from a year earlier.

    Does PDSB pay a dividend?

    No. PDS Biotechnology does not pay a dividend.

    How much debt does PDSB have?

    PDS Biotechnology has $1.09K of total debt and $15.25M of cash and equivalents, a net cash position of $15.24M.